Article
Medicine, General & Internal
Shuhei Yoshida, Yuya Sumichika, Kenji Saito, Haruki Matsumoto, Jumpei Temmoku, Yuya Fujita, Naoki Matsuoka, Tomoyuki Asano, Shuzo Sato, Kiyoshi Migita
Summary: This study investigated the clinical features and treatment response of Japanese patients with FMF. It found that colchicine was effective in the majority of patients, but some patients showed resistance to colchicine. Canakinumab showed good efficacy in colchicine-resistant patients.
JOURNAL OF CLINICAL MEDICINE
(2023)
Review
Pharmacology & Pharmacy
Dimitri Poddighe, Micol Romano, Facundo Garcia-Bournissen, Erkan Demirkaya
Summary: Familial Mediterranean fever (FMF) is commonly diagnosed in childhood and is treated predominantly with colchicine, but in cases of intolerance or resistance, the use of biologics, especially interleukin-1 antagonists, should be considered.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
(2022)
Review
Rheumatology
Berkay Kilic, Yelin Guler, Feyza N. Azman, Ece Bostanci, Serdal Ugurlu
Summary: This study aimed to evaluate the efficacy and safety of anti-IL-1 agents in FMF patients. The results showed that anti-IL-1 agents significantly decreased levels of inflammatory markers and demonstrated good efficacy and low adverse events in adult and pediatric FMF patients.
Article
Pediatrics
Burcu Bozkaya Yucel, Ozlem Aydog, Hulya Nalcacioglu, Aysegul Yilmaz
Summary: The study retrospectively analyzed 65 FMF patients who received canakinumab treatment due to colchicine resistance or intolerance. The results showed that canakinumab treatment was highly effective, well-tolerated in pediatric FMF patients, and controlled extension of the canakinumab dose interval was safe, with no severe adverse effects observed.
FRONTIERS IN PEDIATRICS
(2021)
Article
Rheumatology
Seher Sener, Veysel Cam, Ezgi Deniz Batu, Muserref Kasap Cuceoglu, Zeynep Balik, Emil Aliyev, Yagmur Bayindir, Ozge Basaran, Yelda Bilginer, Seza Ozen
Summary: This study aimed to establish a treatment management and discontinuation protocol for paediatric FMF patients treated with canakinumab. The protocol involved gradually reducing the frequency of canakinumab administration over time. Results showed that more than half of the patients were able to successfully discontinue canakinumab treatment within 18 months.
Article
Rheumatology
B. Sozeri, H. E. Sonmez, S. G. Karadag, E. Baglan, K. Ozturk, M. Cakan, F. Demir, G. Otar Yener, S. Ozdel, N. Aktay Ayaz
Summary: The study suggests that withdrawing or extending the dose interval of canakinumab may be feasible in pediatric patients with colchicine-resistant familial Mediterranean fever. Some patients experienced new attacks after withdrawal, while others remained symptom-free.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY
(2021)
Article
Rheumatology
Erdem Suticen, Nuh Atas, Aslihan Avanoglu Guler, Orhun Akdogan, Hakan Babaoglu, Hasan Satis, Hazan Karadeniz, Seminur Haznedaroglu, Mehmet Akif Ozturk, Abdurrahman Tufan
Summary: The study revealed significant impairments in quality of life in FMF patients and higher levels of work productivity impairment compared to healthy subjects, with factors such as attack frequency, disease activity, colchicine resistance, and disease-related damage correlated with work impairment. The use of IL-1 antagonists may help improve work productivity and quality of life in FMF patients with frequent attacks.
CLINICAL RHEUMATOLOGY
(2021)
Review
Medicine, General & Internal
B. H. Egeli, S. Ugurlu
Summary: As inflammation research improves, our understanding of autoinflammatory conditions also increases. Familial Mediterranean fever (FMF), being the entrance to this field, is still clinically relevant for our understanding of patient management, treatment options, and underlying mechanisms.
QJM-AN INTERNATIONAL JOURNAL OF MEDICINE
(2022)
Article
Rheumatology
A. Druyan, E. Giat, A. Livneh, C. Grossman, I. Ben Zvi, M. Lidar
Summary: The study concluded that canakinumab is an effective treatment for familial Mediterranean fever after failure of anakinra for any reason. Patients who switched to canakinumab from anakinra showed a significant decrease in flare frequency, duration of flares, severity of pain, and overall assessment of disease activity.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY
(2021)
Article
Rheumatology
Takuya Tomokawa, Tomohiro Koga, Yushiro Endo, Toru Michitsuji, Atsushi Kawakami
Summary: This study suggests that canakinumab is effective and safe for use in Japanese patients with colchicine-resistant or colchicine-intolerant familial Mediterranean fever (FMF) in a real-world clinical setting in Japan.
MODERN RHEUMATOLOGY
(2022)
Article
Rheumatology
Avishai M. Tsur, Abdulla Watad, Omer Gendelman, Daniel Nissan, Arnon D. Cohen, Howard Amital
Summary: The study found a positive association between FMF and asthma through a cross-sectional study. Further research is needed to validate and explore possible explanations for this association. These findings challenge previous studies that suggested FMF as a protective factor against asthma.
Article
Medicine, General & Internal
Haruki Matsumoto, Kenji Saito, Yuya Sumichika, Shuhei Yoshida, Jumpei Temmoku, Yuya Fujita, Naoki Matsuoka, Tomoyuki Asano, Shuzo Sato, Kiyoshi Migita
Summary: Familial Mediterranean fever (FMF) is a genetic autoinflammatory disease characterized by recurrent episodes of fever, serositis, and synovitis. The synovitis attacks in FMF present as acute monoarthritis with pain and hydrarthrosis, which resolve spontaneously. Colchicine is effective in preventing these painful arthritis attacks in FMF, but distinguishing them from other febrile attacks with various clinical manifestations is crucial.
TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE
(2023)
Article
Rheumatology
Yusuf Karabulut, Halise Hande Gezer, Nuran Oz, Irfan Esen, Mehmet Tuncay Duruoz
Summary: This study investigated the disease characteristics of FMF patients undergoing dose optimisation and discontinuation of canakinumab therapy. The results showed that canakinumab is a safe and effective treatment, and the dosing interval may be extended, allowing for follow-up without medication for eligible patients.
RHEUMATOLOGY INTERNATIONAL
(2022)
Article
Rheumatology
Yusuf Karabulut, Halise Hande Gezer, Mehmet Tuncay Duruoez
Summary: This study presented the real-life experience of using canakinumab in adult patients with Familial Mediterranean fever resistant to standard therapy from two rheumatology clinics. The research found that canakinumab is effective and tolerable in reducing attacks in resistant FMF patients, suggesting it may be another treatment option for those who are non-responsive to colchicine and/or anakinra. Further studies with larger patient samples are needed to validate these findings.
RHEUMATOLOGY INTERNATIONAL
(2022)
Article
Rheumatology
Elif Arslanoglu Aydin, Esra Baglan, Nesibe Gokce Kocamaz, Ilknur Bagrul, Serife Tuncez, Semanur Ozdel
Summary: This study aims to evaluate the effect of canakinumab on growth parameters in children with familial Mediterranean fever (FMF). A retrospective analysis was conducted on 946 pediatric FMF patients, of whom 37 were treated with canakinumab. The study found that canakinumab treatment significantly increased weight scores and BMI values, but had no effect on height scores.
CLINICAL RHEUMATOLOGY
(2023)